Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product lines include joint health (ORTHOVISC, MONOVISC), ophthalmic viscoelastics (AMVISC), veterinary products (HYVISC), and aesthetic dermatology (ELEVESS). The company relies on strategic partnerships for distribution, including DePuy Mitek (J&J) for ORTHOVISC in the U.S. and Bausch & Lomb for ophthalmic products.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 |
Nine Months Ended Sep 30, 2008 |
Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Total Revenue | $9,205,015 | $26,813,983 | $21,202,988 |
| Net Income | $1,104,203 | $2,534,690 | $4,361,858 |
| Diluted EPS | $0.10 | $0.22 | $0.38 |
| Operating Cash Flow | N/A | $2,220,091 | $6,618,094 |
| Cash & Equivalents | $35,368,244 | $35,368,244 | $47,167,432 (Jan 1, 2007) |
| Total Debt | $8,000,000 | $8,000,000 | $0 |
| Product Gross Margin | 58.9% | 58.2% | 54.4% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15.6% year-over-year for the quarter and 26.5% for the nine-month period. Product revenue grew 17.0% (quarter) and 30.4% (nine months).
- Profitability Decline: Net income decreased 38.5% for the quarter and 41.9% for the nine-month period compared to 2007. This was driven by increased operating expenses and lower interest income.
- Expense Increases:
- R&D: Increased 60.0% (quarter) and 66.9% (nine months) due to clinical trials for MONOVISC and CINGAL, and manufacturing scale-up.
- SG&A: Increased 41.0% (quarter) and 66.6% (nine months) due to marketing for ELEVESS, new facility costs, and legal/consulting fees.
- Capital Expenditures: Investing cash outflows increased significantly to $11.4 million (nine months) from $9.8 million, primarily due to the $15 million spent on the new Bedford, MA facility.
- Debt Financing: The company entered a $16 million credit facility with Bank of America in January 2008 and had $8 million outstanding as of September 30, 2008.
Outlook, Risks, and Management Commentary
- Product Launches: MONOVISC and ORTHOVISC mini launched in Europe/Turkey in Q2 2008, driving joint health revenue growth. ELEVESS launched in the U.S. in August 2008 with Artes Medical, Inc.
- Facility Expansion: The company is constructing a new $30 million facility in Bedford, MA, expected to be occupied in 2010. Approximately $27 million has been spent to date.
- Regulatory Matters:
- FDA Warning Letter: Received in July 2008 regarding the Woburn facility. Management responded in September 2008 and expects clearance by early 2009 following a re-inspection.
- Trademark Opposition: Colbar Lifescience (J&J subsidiary) opposes the ELEVESS trademark. The company believes the claim is without merit and is exploring settlement.
- Tax Outlook: The effective tax rate decreased to 26.7% (nine months) due to Massachusetts investment tax credits. The extension of the federal research tax credit (passed Oct 3, 2008) is expected to favorably impact the full-year rate.
- Liquidity: Management expects cash requirements to increase due to facility build-out and operating expenses. The company plans to fund these via cash on hand and the existing credit facility.
Key Investor Verification Points
- FDA Compliance: Verify the timeline and outcome of the FDA re-inspection regarding the Warning Letter issued in July 2008.
- Facility Costs: Monitor capital expenditure burn rate for the new Bedford facility and potential need for additional financing beyond the current $16 million credit line.
- Trademark Litigation: Track the status of the ELEVESS trademark opposition filed by Colbar Lifescience and potential impact on the aesthetic product line.
- Revenue Mix: Assess the sustainability of the 52.5% growth in joint health revenue and the impact of the new ELEVESS distribution agreement on future aesthetic sales.
- Debt Covenants: Review the company's ability to maintain the required quick ratio and fixed charge coverage ratio under the Bank of America credit agreement.